Homepage / Science & Technology

Science & Technology

Groundbreaking medical technology for the diagnosis of the most extraordinary genetic disorders

We have designed our technology to overcome current technical shortcomings and help healthcare systems move towards a more cost-effective and sustainable path for disease diagnosis.

We  combine genomics, AI/Machine Learning & blockchain technologies, and provide a shorter, safer & economical path to accurate diagnosis ensuring the highest security & patient data encryption. 


Our technology received approval from the European authorities in May 2022 and is currently the only IVD certified technology with real-time data analysis, with hundreds of samples’ simultaneous analysis in less than 24 hrs, high accuracy (sensitivity/specificity >99%), low limit of detection (to address mosaicism), detection of tandem repeats, unclassified reads 7% vs. 24% with NGS, at a much lower price.



See how the gMendel® technology compares to conventional sequencing techniques

Currently, the diagnosis of genetic disorders relies on low-accurate conventional methods such as karyotyping (FISH), chromosomal microarrays (CMA), optical genome mapping (OGM), Sanger sequencing, comparative genome hybridization (CGH) arrays and MLPA- & PCR-based techniques.

In addition, advanced technologies such as next generation sequencing and genomics/AI solutions, are still characterized by high complexity, high cost and high risk for patients, particularly in the case of Laboratory Developed Tests (LDTs), which are designed, manufactured and used within a single laboratory.

As a result, even after dozens of medical examinations, which take many years, significant number of patients are still misdiagnosed, creating a heavy human, economic and societal burden. There is an apparent unmet clinical need for better, faster and affordable screening/diagnosis of wide range of genetic disorders.

The gMendel®️ technology is the only proprietary technology that bridges the gap between genomic sequencing & AI, offering a paradigm shift in detection of genetic disorders.

  • Accurate, sensitive & specific
    It holds 97% analytical sensitivity, 99.1% analytical specificity and 98% accuracy, thus reducing inconclusive results and the need to repeat testing.
  • Cost-efficient
    It provides real-time and simultaneous analysis of up to 384 patient samples in less than 24 hours, which can bring down costs by a staggering 90%.
  • Rapid and scalable
    It is flexible and performs on-demand processing of several hundreds of patients’ samples per run due to our proprietary multilevel multiplexing method, Phivea®.
  • Reliable
    It can sequence any length of DNA fragment, from short to ultra-long, thus allowing more genetic variation characterization and versatility for to broad applications.
  • AI-driven
    It provides scalable genomic interpretation with a suite of ground-breaking algorithms.
  • User friendly
    It requires minimal training and hands-on knowledge.
  • Safe
    It is CE-marked and certified as an IVD medical device product under the Directive 98/79/EC for In Vitro Diagnostic medical devices. Following versions of Phivea®️ platform shall be CE-marked and certified as an IVD medical device product under the Regulation (EU) 2017/746 (IVDR) of the European Parliament for In Vitro Diagnostic medical devices.
  • Secure
    It ensures highest security and patient data encryption through the use of private blockchains.